logo

For the Inventor, By the Inventor

La Jolla, CA, United States of America

Ambrx, Inc.


USPTO Granted Patents = 113



Trademarks = 2

Forward Citations = 1,508

Loading Chart...
Loading Chart...

86 inventors (with patents filed for the assignee):

goldMedal Nick Knudsen (36 out of 37 patents)

silverMedal Feng Tian (29 out of 35 patents)

bronzeMedal Thea Norman (29 out of 39 patents)

4.  Vadim Kraynov (28 out of 31 patents)

5.  Ho Sung Cho (28 out of 29 patents)

6.  Zhenwei Miao (27 out of 49 patents)

7.  Jason Pinkstaff (27 out of 27 patents)

8.  Anna-Maria A Hays Putnam (26 out of 26 patents)

9.  Junjie Liu (20 out of 36 patents)

10.  Troy Edward Wilson (17 out of 55 patents)

11.  Anna-Maria A Hays (15 out of 15 patents)

12.  Russell Driver (14 out of 15 patents)

13.  Thomas O Daniel (13 out of 15 patents)

14.  Stephanie Chu (12 out of 12 patents)

15.  Lorraine Sullivan (11 out of 11 patents)


Core Competencies:
Antibody Drug Conjugates
Modified Relaxin Polypeptides
Non-Natural Amino Acids
FGF-21 Polypeptides
Prostate-Specific Membrane Antigen
Porcine G-CSF Variants
Anti-CD3 Antibodies
Therapeutic Applications
Hybrid Suppressor tRNA
Nucleic Acids Encoding Polypeptides
Bioconjugates
Intracellular Delivery

113 patents:

1. 12404512 - Method for optimizing antibody expression (2025-09-02),
2. 12377294 - Anti-CD3 antibody folate bioconjugates and their uses (2025-08-05),
3. 12286462 - Porcine G-CSF variants and their uses (2025-04-29),
4. 12059473 - Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates (2024-08-13),
5. 12049485 - Interleukin-2 polypeptide conjugates and their uses (2024-07-30),
6. 12037405 - Anti-CD70 antibody drug conjugates (2024-07-16),
7. 11993637 - Modified FGF-21 polypeptides with non-naturally encoded amino acids (2024-05-28),
8. 11851662 - Methods and compositions for promoting non-natural amino acid-containing protein production (2023-12-26),
9. 11851488 - Anti-CD3-folate conjugates and their uses (2023-12-26),
10. 11786578 - Modified relaxin polypeptides and their uses (2023-10-17),
11. 11773150 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors (2023-10-03),
12. 11578111 - Porcine G-CSF variants and their uses (2023-02-14),
13. 11542310 - Modified bovine G-CSF polypeptides and their uses (2023-01-03),
14. 11510993 - Antibody drug conjugate for anti-inflammatory applications (2022-11-29),
15. 11459392 - Anti-CD70 antibody drug conjugates (2022-10-04),
AMBRx, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformative protein therapeutics using an expanded genetic code technology. Their proprietary technology enables the site-specific incorporation of amino acids beyond the 20 naturally occurring ones, resulting in novel, optimized therapeutic proteins with enhanced properties. AMBRx aims to address unmet medical needs and deliver innovative treatments for cancer, metabolic disorders, and other serious diseases.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

113 Patents

#5 in La Jolla, CA

#760 in California

#3,263 in US

#6,799 in the World

...
La Jolla, CA, United States of America

Ambrx, Inc.

Forward Citations = 1,508

86 inventors:

goldMedal Nick Knudsen (36 out of 37 patents)

silverMedal Feng Tian (29 out of 35 patents)

bronzeMedal Thea Norman (29 out of 39 patents)

4.  Vadim Kraynov (28 out of 31 patents)

5.  Ho Sung Cho (28 out of 29 patents)

Please report any incorrect information to support@idiyas.com
Loading…